| Dr Nicholas Larry Deep, MD | |
|
13400 E Shea Blvd, Scottsdale, AZ 85259-5452 | |
| (480) 301-8000 | |
| Not Available |
| Full Name | Dr Nicholas Larry Deep |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 11 Years |
| Location | 13400 E Shea Blvd, Scottsdale, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528403888 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Hospital | Phoenix, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic - Arizona | 7012829930 | 1395 |
News Archive
Pharmaceuticals, Inc. today announced interim results of a randomized, open‐label, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer. Based on this interim analysis, the study demonstrated a statistically significant improvement in the primary endpoint of median progression-free survival (PFS) in patients receiving single-agent ridaforolimus compared to patients receiving standard-of-care treatment.
Hormone concentrations during early fetal development - that may affect the child's development and increase the mother's risk for breast and ovarian cancer years later - are significantly affected by maternal age, body mass index and race rather than lifestyle, according to a Rutgers study.
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.
In a groundbreaking policy paper released today, the American College of Physicians (ACP) offered more than a dozen principles for engaging the public in a process that it hopes will lead to consensus on conserving and allocating resources based on the best evidence of clinical effectiveness and value.
› Verified 7 days ago
| Entity Name | Mayo Clinic Arizona |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558332494 PECOS PAC ID: 7012829930 Enrollment ID: O20031105000782 |
News Archive
Pharmaceuticals, Inc. today announced interim results of a randomized, open‐label, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer. Based on this interim analysis, the study demonstrated a statistically significant improvement in the primary endpoint of median progression-free survival (PFS) in patients receiving single-agent ridaforolimus compared to patients receiving standard-of-care treatment.
Hormone concentrations during early fetal development - that may affect the child's development and increase the mother's risk for breast and ovarian cancer years later - are significantly affected by maternal age, body mass index and race rather than lifestyle, according to a Rutgers study.
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.
In a groundbreaking policy paper released today, the American College of Physicians (ACP) offered more than a dozen principles for engaging the public in a process that it hopes will lead to consensus on conserving and allocating resources based on the best evidence of clinical effectiveness and value.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nicholas Larry Deep, MD 13400 E Shea Blvd, Scottsdale, AZ 85259-5499 Ph: (480) 301-8000 | Dr Nicholas Larry Deep, MD 13400 E Shea Blvd, Scottsdale, AZ 85259-5452 Ph: (480) 301-8000 |
News Archive
Pharmaceuticals, Inc. today announced interim results of a randomized, open‐label, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer. Based on this interim analysis, the study demonstrated a statistically significant improvement in the primary endpoint of median progression-free survival (PFS) in patients receiving single-agent ridaforolimus compared to patients receiving standard-of-care treatment.
Hormone concentrations during early fetal development - that may affect the child's development and increase the mother's risk for breast and ovarian cancer years later - are significantly affected by maternal age, body mass index and race rather than lifestyle, according to a Rutgers study.
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.
In a groundbreaking policy paper released today, the American College of Physicians (ACP) offered more than a dozen principles for engaging the public in a process that it hopes will lead to consensus on conserving and allocating resources based on the best evidence of clinical effectiveness and value.
› Verified 7 days ago
Annica Cooper Eells, Otolaryngology Medicare: Medicare Enrolled Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-351-8000 | |
Lisa D Grunebaum, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Pedro Gomes, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Dr. Paul Kenneth Holden, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 15757 N 78th St, Suite A, Scottsdale, AZ 85260 Phone: 480-787-5815 Fax: 480-787-5814 | |
Dr. Kurt Edward Heiland, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 8752 E Via De Commercio Ste 1, Scottsdale, AZ 85258 Phone: 480-684-1080 Fax: 480-684-1080 | |
Dr. Jordan Seth Weiner, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 8952 E Desert Cove Ave, Suite 205, Scottsdale, AZ 85260 Phone: 480-273-8688 Fax: 480-273-8689 | |
Dr. Amar Miglani, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 |